Results 141 to 150 of about 29,210 (297)

Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single‐Center Retrospective Analysis

Cancer Reports, Volume 8, Issue 10, October 2025.
ABSTRACT Background Hairy cell leukemia (HCL) is a rare disorder characterized by splenomegaly, pancytopenia, and proliferation with “hairy” lymphocytes. Treatment is based on purine analogs and anti‐CD20 antibodies, often resulting in significant adverse effects.
M. Garcia Fasanella, A. Mozos, J. Briones, J. F. Nomdedeu, S. Novelli   +4 more
wiley   +1 more source

CXCR4 WHIM‐like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88^L265P‐directed survival signalling in Waldenström macroglobulinaemia cells [PDF]

, 2014
Yang Cao, Zachary R. Hunter, Xia Liu, Lian Xu, Guang Yang, Jie Chen, Nickolas Tsakmaklis, Sandra Kanan, Jorge J. Castillo, Steven P. Treon   +9 more
openalex   +1 more source

Uncovering regulatory B‐cell features associated with regulatory T‐cell expansion and global T‐cell exhaustion in Waldenström macroglobulinemia Myd88L252P‐like lymphoplasmacytic lymphomas

HemaSphere, Volume 9, Issue 10, October 2025.
Abstract Waldenström's macroglobulinemia (WM) is a rare, indolent lymphoproliferative disorder, genetically characterized by the presence of the L265P mutation in the MYD88 gene in almost all cases, resulting in constitutive activation of NF‐kappa B (NF‐κB). Despite its slow progression, WM remains incurable due to the lack of specific treatments.
Quentin Lemasson, Maxime Tabaud, Ophélie Téteau, Bastien Carle, Mina Chabaud, Jean Feuillard, Nathalie Faumont, Christelle Vincent‐Fabert   +7 more
wiley   +1 more source

Ibrutinib inhibits SDF1/CXCR4 mediated migration in AML [PDF]

, 2014
Lyubov Zaitseva, Megan Y. Murray, Manar Shafat, Matthew Lawes, David J. MacEwan, Kristian M. Bowles, Stuart A. Rushworth   +6 more
openalex   +1 more source

Ibrutinib Resistance in Chronic Lymphocytic Leukemia [PDF]

, 2014
Gustaaf Reurink, Gert Jan Goudswaard, Maarten H. Moen, Adam Weir, Jan A.N. Verhaar, Marco Sita, Mario Maas, Johannes L. Tol   +7 more
openalex   +1 more source

Ibrutinib is an effective treatment of autoimmune haemolytic anaemia in chronic lymphocytic leukaemia [PDF]

, 2015
Sudhir Manda, Nancy M. Dunbar, Cynthia R. Marx‐Wood, Alexey V. Danilov   +3 more
openalex   +1 more source

Ibrutinib and Rituximab in Waldenström’s Macroglobulinemia [PDF]

New England Journal of Medicine, 2018
Gian Matteo Rigolin, Francesco Cavazzini, Antonio Cuneo   +2 more
openaire   +4 more sources

Ibrutinib Promotes Atrial Fibrillation by Disrupting A-Kinase Anchoring Protein 1-Mediated Mitochondrial Quality Surveillance in Cardiomyocytes

Research
Background: Ibrutinib, a potent Bruton’s tyrosine kinase inhibitor with marked efficacy against hematological malignancies, is associated with the heightened risk of atrial fibrillation (AF).
Yukun Li, Xinmeng Liu, Rong Lin, Xiaodong Peng, Xuesi Wang, Fanchao Meng, Shuqi Jin, Wenhe Lv, Xiaoying Liu, Zhuohang Du, Songnan Wen, Rong Bai, Yanfei Ruan, Hao Zhou, Rongjun Zou, Ribo Tang, Nian Liu   +16 more
doaj   +1 more source

NOTCH1 Mutation Is Associated With Response to Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia: A Retrospective Study

eJHaem, Volume 6, Issue 5, October 2025.
ABSTRACT Background Chronic lymphocytic leukemia (CLL) treatment choice remains a challenge in the era of molecular biology and targeted therapy. Methods We conducted a bicentric retrospective analysis of the impact of NOTCH1 mutation according to the treatment of CLL patients in real life.
Clémence Haméon, Roch Houot, Emmanuel Gyan, Nicolas Vallet, Sébastien Lachot, Michel Ganard, Olivier Herault, Sophie De Guibert, Cédric Pastoret, Caroline Dartigeas   +9 more
wiley   +1 more source

Life after ibrutinib? A new unmet need in CLL [PDF]

, 2015
Javier Pinilla‐Ibarz, Julio C. Chávez
openalex   +1 more source